Outcomes of a multidisciplinary team approach to cardiovascular risk reduction in patients with diabetes mellitus

Introduction: Cardiovascular risk reduction can decrease morbidity and mortality in patients with diabetes mellitus; however, it is seldom optimally achieved with standard care. Methods: We herein report on the rationale and preliminary results of a clinic model using a multidisciplinary team approach to improve cardiovascular risk management in patients with diabetes mellitus. We assessed risk-factor management for glycemia, dyslipidemia, hypertension and lifestyle in a retrospective survey of patients followed for 1 year or longer, in comparison with cardiology practice patients in a separate clinic at the same institution. Results: We demonstrated that intervention by a team including a cardiologist, endocrinologist, certified diabetes educator, dietician, cardiovascular advanced practice nurses and an exercise physiologist resulted in a high percentage of patients at National Cholesterol Education Program goals for secondary prevention of coronary artery disease compared with standard care. A comparis...

[1]  M. Engelgau,et al.  The Evolving Diabetes Burden in the United States , 2004, Annals of Internal Medicine.

[2]  R. Bonow,et al.  The diabetes epidemic: a national and global crisis. , 2004, The American journal of medicine.

[3]  G. Putzer,et al.  Compliance with recommendations for lipid management among patients with type 2 diabetes in an academic family practice. , 2004, The Journal of the American Board of Family Practice.

[4]  H. Black,et al.  Guidelines for Hypertension: Are Quality-Assurance Measures on Target? , 2004, Hypertension.

[5]  S. Saydah,et al.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.

[6]  J. Rosenstock,et al.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.

[7]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[8]  J. Plutzky,et al.  Prediabetes mellitus and its links to atherosclerosis , 2003, Current diabetes reports.

[9]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[10]  K. Zulkowski,et al.  Adherence to American Diabetes Association standards of care by rural health care providers. , 2002, Diabetes care.

[11]  H. von Gizycki,et al.  Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. , 2002, Diabetes care.

[12]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[13]  S. Hampson.  Randomised, placebo-controlled trial , 2002 .

[14]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[15]  W. O’Neill,et al.  Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines? , 2001, American heart journal.

[16]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[17]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[18]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[19]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[20]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[21]  M. Harris,et al.  Mortality in Adults With and Without Diabetes in a National Cohort of the U.S. Population, 1971–1993 , 1998, Diabetes Care.

[22]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[23]  K. Malmberg.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[24]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[25]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[26]  V. Barriales,et al.  [Heart disease and diabetes]. , 1991, Medicina clinica.

[27]  P. Wilson,et al.  The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. , 1988, JAMA.

[28]  M. Taskinen,et al.  Insulin Therapy Induces Antiatherogenic Changes of Serum Lipoproteins in Noninsulin‐Dependent Diabetes , 1988, Arteriosclerosis.

[29]  Diabetes in America—National Diabetes Data Group , 1986, Diabetes Care.

[30]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .